Theravance Biopharma, Inc. (TBPH) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2026. Theravance Biopharma is a biopharmaceutical company focused on the development and commercialization of medicines, primarily YUPELRI (revefenacin) for COPD. The company operates as a single segment. A significant corporate development occurred on June 28, 2026, when the company entered into a definitive agreement to be acquired by Zymeworks Inc.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| Total Revenues | $38,430 |
| Net Loss | $(10,831) |
| Net Loss Per Share (Basic & Diluted) | $(0.21) |
| Cash, Cash Equivalents, and Marketable Securities | $387,657 |
| Net Cash Provided by Operating Activities | $66,314 |
| Total Assets | $469,770 |
| Total Liabilities | $179,065 |
| Shareholders' Equity | $289,705 |
Note: The company reported no long-term debt. The "Future royalty payment contingency" liability of $32.795 million is classified as a long-term liability.
Material Changes vs. Prior Period
- Revenue: Total revenue decreased by 8% year-over-year (from $41.6M to $38.4M). This decline was driven by the absence of a $7.5M licensing milestone recognized in the prior year related to YUPELRI's China regulatory approval. However, revenue from the Viatris collaboration increased 13% to $38.4M due to a 7% increase in YUPELRI net sales.
- Net Income/Loss: The company reported a net loss of $10.8M, compared to net income of $41.3M in the prior year. The prior year's income was significantly boosted by a $75.1M net gain on the sale of TRELEGY royalty assets, which did not recur in the current period.
- Expenses:
- R&D Expenses: Decreased 52% to $10.5M, primarily due to the winding down of the ampreloxetine CYPRESS program and organizational restructuring.
- SG&A Expenses: Decreased 13% to $31.9M, driven by cost savings from restructuring and reduced pre-commercial launch expenses.
- Restructuring Expenses: The company incurred $7.7M in restructuring expenses (non-existent in the prior year) related to a 50% workforce reduction.
- Transaction-Related Expenses: Incurred $6.1M related to the pending merger with Zymeworks.
- Interest Expense: Non-cash interest expense on the ampreloxetine royalty contingency ceased in Q1 2026 following the failure of the CYPRESS Phase 3 study, resulting in $0 interest expense for the period compared to $1.3M in the prior year.
Guidance, Outlook, and Material Events
- Pending Merger: On June 28, 2026, Theravance Biopharma agreed to be acquired by Zymeworks Inc. Shareholders will receive $17.00 per share in cash plus a Contingent Value Right (CVR). The CVR entitles shareholders to 80% of net proceeds from any future license or monetization of ampreloxetine over the next ten years, plus a $50M milestone payment upon first commercial sale in specific markets, and 10% of net sales royalties. The merger is expected to close in the second half of 2026.
- Ampreloxetine Program: The Phase 3 CYPRESS study failed to meet its primary endpoint in March 2026. The company is winding down the program but will continue targeted regulatory and IP activities to maximize value for the CVR.
- Organizational Restructuring: Initiated in March 2026 to align resources with the commercial focus on YUPELRI. The company reduced headcount by approximately 50% (90 employees) and expects full run-rate cost savings of approximately $70 million to be realized in the second half of 2026.
- TRELEGY Milestones: The company received a $50.0M milestone payment from Royalty Pharma in February 2026. It remains eligible for up to $100.0M in additional milestone payments in 2026 based on TRELEGY global net sales thresholds.
- Liquidity: Management expects cash and marketable securities to be sufficient to fund operations for at least the next 12 months, assuming the completion of the merger.
Key Facts for Investor Verification
- Merger Terms: Verify the specific conditions for the Zymeworks merger closing and the detailed mechanics of the Contingent Value Rights (CVRs), including the 10-year timeline and royalty percentages.
- Restructuring Costs: Confirm the total estimated cash severance ($6.0M-$7.0M) and non-cash equity modification costs ($4.5M-$5.5M) and the timeline for their recognition.
- YUPELRI Sales Growth: Monitor the 7% year-over-year sales growth of YUPELRI and the impact of the settled generic patent litigation (launch date set for April 23, 2039) on future pricing and market share.
- TRELEGY Milestone Triggers: Verify the specific global net sales thresholds required to trigger the remaining $100M in potential milestone payments from Royalty Pharma in 2026.
- Ampleloxetine Future Value: Assess the likelihood of future regulatory pathways for ampreloxetine following the FDA Type B meeting, as this directly impacts the value of the CVRs.